Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
Key claim: The FDA is classifying the Spinal Muscular Atrophy newborn screening test system into Class II (special controls) to provide reasonable assurance of safety and effectiveness while reducing regulatory burdens and enhancing patient access.
Abstract
(Rule · Health and Human Services Department, Food and Drug Administration) The Food and Drug Administration (FDA) is classifying the Spinal Muscular Atrophy newborn screening test system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the Spinal Muscular Atrophy newborn screening test system. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients’ access to beneficial innovative devices, in part by reducing regulatory burdens.
Why this matters
Classifying the SMA newborn screening test system as Class II with special controls establishes a defined regulatory pathway for these tests, allowing manufacturers to seek 510(k) clearance rather than pursue premarket approval. Early detection of SMA enables timely access to disease-modifying therapies, so a clearer regulatory route can support broader availability of screening in state newborn screening programs.